| 1 |
34716196 | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. | 2022 Jan 15 |
2 |
| 2 |
33832508 | Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib. | 2021 Apr 8 |
1 |
| 3 |
34103301 | Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | 2021 Jul 15 |
4 |
| 4 |
32330242 | A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. | 2020 Apr 28 |
8 |
| 5 |
32943455 | Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. | 2020 Dec 1 |
1 |
| 6 |
31213500 | A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. | 2019 Oct |
1 |
| 7 |
31602563 | Pexidartinib: First Approval. | 2019 Nov |
2 |
| 8 |
25993548 | Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer. | 2015 Sep |
1 |